Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are…
17/08/2021 - 5 minutes
Respiratory disease
How Will We Be Treating Cystic Fibrosis 10 Years From Now?
Current treatments for cystic fibrosis are not suitable for all patients and have a limited…
24/03/2020 - 9 minutes
Viral Vaccines Could Be Weapons Against Alzheimer’s Disease
Scientists in Sweden have found that some viruses can increase the buildup of protein ‘plaques’…
28/05/2019 - 3 minutes
Inhaled Lung Disease Treatment Encounters Mixed Results in Phase II Trial
An inhaled drug from British company Verona Pharma has failed to significantly improve lung function…
14/01/2019 - 3 minutes
Cambridge Company Raises €20M for Potential First in Lung Disease
Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments…
20/12/2018 - 1 minute
Smart Asthma Inhaler Fails Phase III
It is bad news for asthma sufferers, as a UK biotech has abandoned the development…
26/11/2018 - 2 minutes
London Biotech Raises €47M to Develop First Treatment Against RSV Virus
ReViral will dedicate the funds to run two clinical trials to test whether its antiviral…
01/08/2018 - 2 minutes
British Biotech Raises £29M Round to Fight Lung Disease
Enterprise Therapeutics has raised a substantial Series B financing round to bring its treatments for…
12/04/2018 - 2 minutes
Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment
Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody…
05/03/2018 - 2 minutes
How is Actelion Spin-Off Idorsia Doing One Year Later?
Actelion's spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How…
01/03/2018 - 3 minutes
Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates
AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the…
06/02/2018 - 3 minutes
New Antiviral for RSV Lung Infections Shows Promise in Phase IIa
ReViral's candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections…
05/02/2018 - 3 minutes
